 |
IDEC Pharmaceuticals Corporation, San Diego, offers Zevalin” (ibritumomab tiuxetan), a new class of cancer treatments called radioimmunotherapies. It is indicated for the treatment of relapsed or refractory low grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma (NHL), including patients with Rituxan? (rituximab) refractory follicular NHL. Zevalin, a monoclonal antibody linked to the radioisotope yttrium-90, targets the CD20 antigen on the surface of mature B cells and B-cell tumors, inducing cellular damage in the target and neighboring cells. (877) 878-4332; www.idecpharm.com .
